NCT05130827View on ClinicalTrials.gov

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Plinabulin

40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

Sponsors
All Listed Sponsors
collaborator

BeyondSpring Pharmaceuticals Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER